Explore the Potential with AI-Driven Innovation
The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.
We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by our associate Reaxense.
The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.
We employ our advanced, specialised process to create targeted libraries.
Fig. 1. The sreening workflow of Receptor.AI
Our methodology leverages molecular simulations to examine a vast array of proteins, capturing their dynamics in both isolated forms and in complexes with other proteins. Through ensemble virtual screening, we thoroughly account for the protein's conformational mobility, identifying critical binding sites within functional regions and distant allosteric locations. This detailed exploration ensures that we comprehensively assess every possible mechanism of action, with the objective of identifying novel therapeutic targets and lead compounds that span a wide spectrum of biological functions.
Our library distinguishes itself through several key aspects:
partner
Reaxense
upacc
Q9Y3Q4
UPID:
HCN4_HUMAN
Alternative names:
-
Alternative UPACC:
Q9Y3Q4; Q9UMQ7
Background:
Potassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 4 plays a pivotal role in heart and neuronal pacemaker mechanisms. It functions as a hyperpolarization-activated ion channel, contributing to the regulation of heart beat rhythm and potentially mediating responses to sour stimuli.
Therapeutic significance:
Linked to Sick sinus syndrome 2, Brugada syndrome 8, and Epilepsy, idiopathic generalized 18, this protein's understanding could pave the way for innovative treatments targeting heart rhythm disorders and epilepsy.